Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: Federal Food, Drug, and Cosmetic Act | Statement: [Title 21 of the United States Code, contains, Federal Food, Drug, and Cosmetic Act]

Target entity: Federal Food, Drug, and Cosmetic Act
Context triple: [Title 21 of the United States Code, contains, Federal Food, Drug, and Cosmetic Act]

• A. Federal Food, Drug, and Cosmetic Act chosen
  The Federal Food, Drug, and Cosmetic Act is a key U.S. law that authorizes the Food and Drug Administration to regulate the safety, labeling, and marketing of food, drugs, medical devices, and cosmetics.
• B. Kefauver–Harris Drug Amendments of 1962
  The Kefauver–Harris Drug Amendments of 1962 are U.S. federal regulations that strengthened drug safety and efficacy requirements, mandating proof of effectiveness and stricter oversight of pharmaceutical marketing and manufacturing.
• C. Food and Drug Administration Modernization Act of 1997
  The Food and Drug Administration Modernization Act of 1997 is a U.S. law that overhauled FDA regulatory procedures to speed the approval of drugs and medical devices while enhancing patient access to experimental therapies and modernizing agency operations.
• D. Dietary Supplement Health and Education Act of 1994
  The Dietary Supplement Health and Education Act of 1994 is a U.S. law that defines and regulates dietary supplements as a category of food, setting labeling and safety standards while limiting the FDA’s pre-market approval authority.
• E. Food and Drug Administration Amendments Act of 2007
  The Food and Drug Administration Amendments Act of 2007 is a U.S. law that expanded the FDA’s authority over drug and device safety, clinical trials, and post-market surveillance, while enhancing transparency and user fee programs.
• F. None of above.
• G. Unsure - the case is ambiguous/there is not enough information to decide.